Promea Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 3.86 Cr
as on 17-07-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 20.71 Cr
as on 17-07-2024
- Revenue 61.53%
(FY 2022)
- Profit -99.18%
(FY 2022)
- Ebitda 10.01%
(FY 2022)
- Net Worth 0.17%
(FY 2022)
- Total Assets 22.12%
(FY 2022)
About Promea Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.86 Cr.
The company currently has active open charges totaling ₹20.71 Cr.
Rajesh Tummuru and Pooja Gaddam serve as directors at the Company.
- CIN/LLPIN
U24304TG2017PTC118617
- Company No.
118617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Patancheru, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Promea Therapeutics Private Limited offer?
Promea Therapeutics Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Promea Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pooja Gaddam  | Director | 31-Jul-2017 | Current |
| Rajesh Tummuru | Director | 09-Oct-2017 | Current |
Financial Performance and Corporate Structure Insights of Promea Therapeutics.
Promea Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 61.53% increase. The company also saw a substantial fall in profitability, with a 99.18% decrease in profit. The company's net worth moved up by a moderate rise of 0.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Promea Therapeutics?
In 2022, Promea Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Promea Care Private Limited
Active 4 years 4 monthsRajesh Tummuru and Pooja Gaddam are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 29 Dec 2022 | ₹1.75 Cr | Open |
Others Creation Date: 24 May 2021 | ₹18.96 Cr | Open |
How Many Employees Work at Promea Therapeutics?
Promea Therapeutics has a workforce of 174 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Promea Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Promea Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
